🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the battle against drug-resistant strains of the pathogen, according to researchers.

A Global Health Concern

Cases of gonorrhoea are increasing around the world, with estimates suggesting in excess of 82 million new cases per year. Especially elevated rates are observed in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely step in the face of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program showed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Secure Approval

One new antibiotic, marketed under the name Nuzolvence, was authorized by the American regulatory agency in December for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers believe that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This medication, which is additionally indicated for UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a innovative non-profit model for medication research. The charitable organization GARDP worked alongside the drug firm Innoviva to see it through.

“This approval marks a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Global Access

Based on findings published in a prominent scientific publication, the new drug successfully treated the vast majority of uncomplicated infections. This puts it on an equal footing with the typical regimen, which involves two antibiotics. The trial included nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the authority to make available and distribute the drug in numerous developing nations.

Clinicians treating patients have voiced hope. Access to a easy-to-administer therapy of this kind is seen as a "critical tool" for public health efforts. This is deemed essential to lessen the impact of the infection for patients and to prevent the spread of extremely resistant gonorrhoea worldwide.